Hypothalamic-Pituitary-Adrenal Axis: How It Works, What Breaks It, and How Clinicians Fix It

What the HPA Axis Actually Does

The HPA axis is a hormonal relay running from the hypothalamus through the anterior pituitary to the adrenal cortex. Corticotropin-releasing hormone (CRH) from the paraventricular nucleus of the hypothalamus travels 2-3 mm down the hypophyseal portal vessels to trigger adrenocorticotropic hormone (ACTH) release from pituitary corticotroph cells. ACTH then drives the adrenal cortex to synthesize cortisol from cholesterol via a series of cytochrome P450 enzymatic steps [1]. Cortisol feeds back negatively on both the pituitary and hypothalamus to suppress further CRH and ACTH secretion, completing the loop [2].

This system operates on two timescales. The first is circadian: cortisol rises sharply in the 60-90 minutes before waking (the cortisol awakening response), peaks near 8 AM, and falls to its nadir around midnight [3]. The second is ultradian, with cortisol secreted in roughly 15-20 pulses per 24 hours [4]. Stress of any kind, whether surgical trauma, hypoglycemia, hemorrhage, or severe infection, triggers a rapid ACTH surge that can push cortisol above 30 mcg/dL within minutes [5]. Without that surge, blood pressure, blood glucose, and immune regulation all fail simultaneously.

The adrenal cortex is anatomically zoned. The zona glomerulosa makes aldosterone. The zona fasciculata makes cortisol. The zona reticularis makes androgens including DHEA-S [6]. ACTH primarily governs the fasciculata; aldosterone regulation runs through the renin-angiotensin-aldosterone system independently. That distinction matters clinically: primary adrenal destruction (Addison's disease) knocks out all three zones, but pituitary-driven secondary adrenal insufficiency spares aldosterone production.

The Normal Feedback Loop: CRH, ACTH, and Cortisol

Negative feedback operates at two anatomical levels. Cortisol binds glucocorticoid receptors (GR) in pituitary corticotrophs to suppress ACTH gene transcription within 15-30 minutes of a cortisol rise [7]. A slower genomic pathway simultaneously suppresses CRH mRNA in the hypothalamus over 1-2 hours [8]. This dual-level inhibition prevents runaway cortisol secretion under ordinary circumstances.

The 1 mg overnight dexamethasone suppression test (DST) exploits this loop. Dexamethasone, a potent synthetic glucocorticoid with no cross-reactivity on standard cortisol immunoassays, is given at 11 PM. A normal pituitary suppresses ACTH overnight, so morning cortisol falls below 1.8 mcg/dL (50 nmol/L) by 8 AM [9]. Failure to suppress suggests autonomous cortisol secretion or pituitary ACTH overproduction. The Endocrine Society 2008 clinical practice guideline on Cushing's syndrome lists the DST as a first-line outpatient screening tool with a sensitivity of approximately 95% at the 1.8 mcg/dL threshold [10].

Addison's Disease: Primary Adrenal Insufficiency

Addison's disease arises when the adrenal cortex itself is destroyed, most commonly by autoimmune adrenalitis (70-90% of cases in high-income countries) [11]. The glands atrophy, cortisol and aldosterone both fall, and ACTH rises steeply because negative feedback is lost. That ACTH elevation causes hyperpigmentation by stimulating melanocortin receptors, a finding specific to primary insufficiency [12].

The ACTH stimulation test (cosyntropin test) confirms the diagnosis. Synthetic ACTH 1-24 (cosyntropin) 250 mcg IV or IM is given, and serum cortisol is measured at 30 and 60 minutes. A peak cortisol <18 mcg/dL (500 nmol/L) is consistent with adrenal insufficiency [13]. Plasma ACTH above 100 pg/mL alongside a failed stimulation test localizes the defect to the adrenal gland itself [14].

Classic biochemistry includes hyponatremia (sodium often 125-135 mEq/L), hyperkalemia, and metabolic acidosis, all reflecting aldosterone deficiency [15]. Fasting hypoglycemia and eosinophilia may also be present. An adrenal crisis, defined by severe hypotension, vomiting, and cardiovascular collapse, is a life-threatening emergency requiring immediate hydrocortisone 100 mg IV bolus followed by 200 mg continuous infusion over 24 hours or 50-100 mg IV every 6 hours [16].

Long-term replacement targets physiological cortisol production, estimated at 5-10 mg/m² per day. Current Endocrine Society guidelines recommend hydrocortisone 15-25 mg/day in two to three divided doses (larger morning dose), supplemented by fludrocortisone 0.05-0.2 mg/day for mineralocorticoid replacement [17]. Patients need written sick-day rules doubling or tripling their hydrocortisone dose during febrile illness and must carry an emergency hydrocortisone injection kit [18].

Secondary Adrenal Insufficiency: The Pituitary or Hypothalamic Failure

Secondary adrenal insufficiency (SAI) stems from insufficient ACTH secretion due to pituitary or hypothalamic pathology, not adrenal destruction. The most common cause globally is exogenous glucocorticoid use; as little as prednisone 5 mg/day for more than three weeks can suppress the HPA axis enough to blunt the cortisol stress response [19]. Other causes include pituitary macroadenomas, Sheehan's syndrome (postpartum pituitary infarction), traumatic brain injury, and cranial irradiation.

Because the zona glomerulosa remains intact and aldosterone secretion is preserved, patients with SAI do not develop the electrolyte pattern typical of Addison's disease. Hyponatremia can still occur, but through a different mechanism: cortisol deficiency impairs free water clearance by increasing antidiuretic hormone (ADH) sensitivity [20]. Hyperkalemia and hyperpigmentation are absent. Plasma ACTH will be low or inappropriately normal despite a low cortisol, which differentiates SAI from primary insufficiency [21].

The low-dose cosyntropin test (1 mcg IV) is considered more sensitive than the standard 250 mcg dose for detecting partial ACTH deficiency, though assay variability limits widespread adoption [22]. Insulin tolerance testing (ITT), using regular insulin 0.1-0.15 units/kg IV to achieve hypoglycemia <40 mg/dL, remains the gold standard for assessing the entire HPA axis reserve when pituitary pathology is suspected [23]. A cortisol rise to at least 18-20 mcg/dL during the ITT confirms adequate axis function.

Treatment mirrors Addison's disease in terms of hydrocortisone dosing but requires no fludrocortisone. The same sick-day rules apply. If the underlying cause is a pituitary tumor, neurosurgical resection or radiation may partially restore ACTH secretion in some patients; recovery of the HPA axis after transsphenoidal surgery should be re-assessed with a cosyntropin test no sooner than 6-8 weeks post-operatively [24].

Cushing's Syndrome: Cortisol Excess and Its Consequences

Cushing's syndrome describes the clinical and metabolic consequences of prolonged supraphysiological cortisol exposure. Exogenous glucocorticoids are by far the most common cause. Endogenous Cushing's syndrome affects 2-3 people per million annually and is subdivided by ACTH dependence [25].

ACTH-dependent Cushing's (roughly 80% of endogenous cases) is driven either by a pituitary corticotroph adenoma (Cushing's disease, covered below) or by ectopic ACTH secretion from a non-pituitary tumor, most often a small-cell lung carcinoma or bronchial carcinoid [26]. ACTH-independent Cushing's arises from autonomous adrenal cortisol secretion by an adenoma, carcinoma, or bilateral hyperplasia.

Classic physical signs include central obesity, moon facies, dorsocervical fat pad ("buffalo hump"), proximal muscle weakness, easy bruising, and wide violaceous striae greater than 1 cm [27]. Metabolic consequences are substantial: hypertension occurs in 75-85% of cases, diabetes or impaired glucose tolerance in 40-70%, osteoporosis is nearly universal with chronic exposure, and standardized mortality ratios (SMR) are 2-5 times that of the general population if left untreated [28].

Screening relies on three biochemical tests, any one of which may be used initially per Endocrine Society guidance [10]:

1. 1 mg overnight DST: morning cortisol <1.8 mcg/dL makes Cushing's unlikely.
2. Late-night salivary cortisol (LNSC): two elevated values (above the lab's 99th percentile) on separate nights are required given intra-individual variability [29].
3. 24-hour urine free cortisol (UFC): values greater than 3-4 times the upper limit of normal are highly specific [10].

A 2022 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=5,367 patients across 37 studies) found the LNSC had pooled sensitivity of 92% and specificity of 96% for Cushing's syndrome diagnosis [30]. Once biochemical hypercortisolism is confirmed, plasma ACTH localizes the source: suppressed ACTH (<10 pg/mL) points to an adrenal lesion; elevated or normal ACTH (>20 pg/mL) indicates ACTH-dependent disease [31].

Cushing's Disease: The Pituitary Adenoma That Drives ACTH

Cushing's disease, a subset of Cushing's syndrome, is caused specifically by an ACTH-secreting pituitary adenoma. It accounts for 70-80% of endogenous Cushing's cases [32]. These tumors are usually microadenomas (diameter <10 mm) and may be undetectable on standard MRI in 40-50% of cases at initial imaging [33].

When pituitary MRI is non-diagnostic, bilateral inferior petrosal sinus sampling (BIPSS) is the definitive test to confirm pituitary ACTH source and lateralize the tumor before surgery. A central-to-peripheral ACTH gradient greater than 2:1 at baseline or 3:1 after CRH stimulation (1 mcg/kg IV ovine CRH) confirms a pituitary source with sensitivity near 95% and specificity near 100% [34].

Transsphenoidal adenomectomy is first-line treatment. Remission rates at experienced pituitary centers reach 65-90% for microadenomas [35]. The Endocrine Society guideline on Cushing's disease defines remission as a morning cortisol below 2 mcg/dL (55 nmol/L) in the first 7 days post-operatively, reflecting removal of the autonomous source and suppression of the remaining normal corticotrophs [36].

When surgery fails or is not feasible, second-line options include repeat surgery, pituitary irradiation (stereotactic radiosurgery achieves remission in 40-60% within 3-5 years), and medical therapy [37]. Approved and commonly used medical agents include:

• Pasireotide (Signifor): a somatostatin receptor ligand that suppresses ACTH; 150-900 mcg SC twice daily; controlled trial data show UFC normalization in 26% at 6 months [38].
• Osilodrostat (Isturisa): an 11-beta-hydroxylase inhibitor; LINC-3 trial (N=137) found 77% UFC normalization at Week 48 [39].
• Mifepristone (Korlym): a glucocorticoid receptor antagonist approved for Cushing's-associated hyperglycemia; 300-1200 mg/day; cannot be monitored by cortisol levels due to receptor blockade [40].
• Ketoconazole 200-1200 mg/day inhibits multiple steroidogenic enzymes and remains widely used off-label, though FDA issued a hepatotoxicity warning in 2013 limiting systemic use [41].

Bilateral adrenalectomy is reserved for patients where all other options have failed or for rapid cortisol control. It guarantees cure of hypercortisolism but risks Nelson's syndrome, aggressive ACTH tumor growth after adrenal removal, occurring in approximately 21% of cases [42].

Diagnosing HPA Axis Disorders: A Step-by-Step Framework

A structured diagnostic sequence prevents the most common clinical errors, specifically missing adrenal insufficiency during acute illness and over-diagnosing Cushing's in patients with pseudo-Cushing states (obesity, depression, alcoholism).

Step 1. Suspicion. Document clinical features. Fatigue plus hyponatremia plus hyperpigmentation raises primary adrenal insufficiency. Central obesity plus hypertension plus diabetes in a patient not on steroids raises Cushing's.

Step 2. Timing of cortisol sample. A random cortisol is rarely diagnostic. Morning (7-9 AM) serum cortisol above 18 mcg/dL makes adrenal insufficiency very unlikely; below 3 mcg/dL is virtually diagnostic of insufficiency [43]. Values in between require dynamic testing.

Step 3. Dynamic testing. For suspected insufficiency: cosyntropin stimulation test. For suspected excess: 1 mg overnight DST, late-night salivary cortisol, or 24-hour UFC. Repeat any borderline test before concluding.

Step 4. ACTH localization. Plasma ACTH (drawn at 8-9 AM into a pre-chilled EDTA tube, centrifuged immediately, and frozen) distinguishes primary from secondary insufficiency, and ACTH-dependent from ACTH-independent Cushing's.

Step 5. Imaging. Adrenal CT for suspected primary disease. Pituitary MRI (3-Tesla, dedicated protocol with thin cuts through the sella) for suspected Cushing's disease or secondary insufficiency. Perform BIPSS before pituitary MRI alone dictates surgery.

Step 6. Confirmatory testing. BIPSS for Cushing's disease localization. Adrenal vein sampling when bilateral adrenal lesions are found. Repeat ITT 6-12 months after pituitary surgery to document HPA recovery.

Long-Term Management and Monitoring

Patients on long-term glucocorticoid replacement for either Addison's disease or secondary adrenal insufficiency require periodic review. Annual monitoring should include blood pressure, weight, bone mineral density (DEXA every 1-2 years), and HbA1c [44]. Over-replacement with hydrocortisone doses above 25 mg/day increases fracture risk and metabolic complications; under-replacement risks adrenal crisis [45].

Cortisol day-curve profiles (serum cortisol measured at multiple points after morning and afternoon doses) can guide dose optimization. Some clinicians use continuous subcutaneous hydrocortisone infusion pumps, which produce more physiological cortisol profiles than oral dosing [46]. A crossover trial (N=64) published in the Journal of Clinical Endocrinology and Metabolism showed that pump infusion improved quality of life scores by 11.3 points on the AddiQoL scale compared to oral therapy [47].

For Cushing's syndrome, post-treatment monitoring focuses on recurrence. After transsphenoidal surgery, annual late-night salivary cortisol and 24-hour UFC monitoring is recommended for at least 10 years given recurrence rates of 15-25% [48]. Bone density typically recovers within 2-5 years of sustained remission, though osteoporotic fracture risk may remain elevated for longer [49].

Patients with adrenal crisis risk must wear medical alert identification and be trained in home injection of hydrocortisone 100 mg IM using a pre-filled syringe. A 2021 audit of adrenal crisis deaths in the UK found that 39% of fatal crises occurred in patients who had not received sick-day rule education from their provider [50].